Blog
CJC-1295 + Ipamorelin UAE: Dual GH Secretagogue Research Guide and Where to Buy (2026)
·
·
5 min read
For research use only. Material is supplied as a lyophilized reference compound with HPLC purity verification.
- Key Facts at a Glance
- What Are CJC-1295 and Ipamorelin?
- How Does the CJC-1295 + Ipamorelin Blend Work?
- CJC-1295 + Ipamorelin Research: Key Findings
- CJC-1295 + Ipamorelin vs Other GH Peptides
Among GH-axis research peptides, the combination of CJC-1295 and Ipamorelin has become one of the most studied protocols in growth hormone secretagogue research. By targeting two distinct but complementary receptors simultaneously — GHRH and ghrelin receptors — this combination produces synergistic GH release that neither compound achieves alone. For UAE researchers investigating body composition, recovery, and GH axis biology, this blend is a cornerstone research tool.
02
What Are CJC-1295 and Ipamorelin?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) modification that dramatically extends its half-life to approximately 6-8 days. By binding to albumin in the blood, CJC-1295 maintains sustained GHRH receptor stimulation, producing a consistent elevation of baseline GH levels throughout the week.
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic that stimulates GH release through an entirely different receptor pathway. Ipamorelin is notable for its high selectivity: it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH — making it one of the cleanest GH secretagogues available for research.
Emirates Peptides supplies CJC-1295 and Ipamorelin as a pre-blended combination vial, simplifying research protocols that require both peptides.
03 · Blend
How Does the CJC-1295 + Ipamorelin Blend Work?
Latest research insights. No spam, ever.
The combination works through dual-pathway GH stimulation:
- CJC-1295 (GHRH pathway): Binds GHRH receptors on pituitary somatotrophs, stimulating baseline GH production and release
- Ipamorelin (Ghrelin pathway): Binds GHSR receptors, amplifying GH pulse amplitude in a synergistic manner
- Combined effect: Research shows the combination produces GH pulses 2-10x greater than either compound alone, while preserving the natural pulsatile release pattern
- IGF-1 upregulation: The elevated GH drives hepatic IGF-1 production, the primary mediator of GH’s anabolic effects
- Selectivity preserved: Ipamorelin’s receptor selectivity means the combination does not significantly elevate cortisol or prolactin — unlike some older GH secretagogues
04 · Research
CJC-1295 + Ipamorelin Research: Key Findings
GH and IGF-1 Elevation
Research consistently demonstrates that CJC-1295 alone produces sustained 2-10 fold increases in GH and IGF-1 levels over baseline. When combined with Ipamorelin, peak GH pulse amplitude is significantly amplified while maintaining physiological pulsatility. A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that CJC-1295 produced dose-dependent increases in GH and IGF-1 that persisted for up to 14 days following a single injection.
Body Composition Research
Multiple research models have investigated the body composition effects of GHRH + GHSR combination protocols. Findings consistently show increased lean mass preservation, reduced visceral adipose tissue, and improved nitrogen balance — effects mediated through the combined anabolic and lipolytic actions of elevated GH and IGF-1.
Recovery and Tissue Repair
GH plays a critical role in collagen synthesis, connective tissue repair, and muscle protein synthesis. Research models investigating GHRH analogues in recovery contexts have shown accelerated healing of musculoskeletal injuries, improved sleep quality, and reduced recovery time — effects attributed to GH-mediated tissue repair pathways.
05 · Other
CJC-1295 + Ipamorelin vs Other GH Peptides
| Peptide | Mechanism | Half-life | Key Research Advantage |
|---|---|---|---|
| CJC-1295 + Ipamorelin | GHRH + Ghrelin dual pathway | 6-8 days / 2 hours | Synergistic GH release, high selectivity |
| Tesamorelin | GHRH analogue only | ~30 mins | Strongest clinical evidence base |
| Sermorelin | GHRH analogue (truncated) | ~10 mins | Short-acting, well-tolerated |
| GHRP-6 | Ghrelin mimetic only | ~15 mins | Strong GH pulse, increases appetite |
06 · Research
Research Dosing Protocol (Reference)
For research reference only. Not approved for human use.
In research protocols, CJC-1295 is typically dosed at 1-2mg once or twice weekly due to its long half-life. Ipamorelin is typically dosed at 100-300mcg at higher frequency (daily to 3x weekly) to time GH pulses. The pre-blended vial from Emirates Peptides simplifies this combined protocol.
Reconstitute with bacteriostatic water and use our peptide calculator for accurate dosing.
Storage
Lyophilised:
2-8°C, protected from light
Reconstituted:
2-8°C, use within 28 days
07
Where to Buy CJC-1295 + Ipamorelin in the UAE
- ✅ Pre-blended combination vial — convenient research format
- ✅ COA-verified, ≥99% purity
- ✅ Fast delivery to Dubai, Abu Dhabi and all UAE emirates
- ✅ GCC shipping available
- ✅ Cash on delivery in Dubai
Order CJC-1295 + Ipamorelin in UAE →
08 · Questions
Frequently Asked Questions
What’s the difference between CJC-1295 DAC and no-DAC?
CJC-1295 DAC (Drug Affinity Complex) has a maleimide modification that binds serum albumin, extending its half-life to ~8 days. Once or twice weekly dosing. CJC-1295 no-DAC has a short half-life of ~30 minutes — used multiple times per day to mimic natural pulsatile GH release. Research endpoint determines which form is appropriate.
Why combine CJC-1295 with Ipamorelin?
They activate two different receptor pathways that both signal GH release. CJC-1295 mimics GHRH on GHRH receptors; Ipamorelin activates ghrelin receptors. Combined activation produces a synergistic GH pulse — research shows the combination produces 2–3× more GH release than either compound alone.
Is Ipamorelin better than GHRP-2 or GHRP-6?
Ipamorelin is more selective for GH release. GHRP-2 and GHRP-6 also raise cortisol and prolactin alongside GH — making them less clean research tools. Ipamorelin’s selectivity is why it’s the preferred ghrelin-receptor agonist in modern GH-axis research.
What is the typical CJC-1295 + Ipamorelin research dose?
100–300 mcg of each, 1–3 times daily subcutaneous. The most common scheduling is one dose pre-bed to align with natural overnight GH pulses, with optional second doses pre-workout or morning. Higher daily frequency mimics natural pulsatile release better.
How does this stack compare to Tesamorelin?
Tesamorelin is a single GHRH analogue with Phase 3 human trial evidence and FDA approval for HIV-lipodystrophy. CJC-1295 + Ipamorelin uses a complementary ghrelin-receptor mechanism alongside GHRH activation, producing larger GH pulses but with less clinical-trial depth. Research endpoint determines which is preferred.
Is CJC-1295 + Ipamorelin legal in the UAE?
Both peptides are supplied strictly for laboratory research use and are not controlled substances in the UAE. Emirates Peptides ships the pre-blended combination vial with batch-specific HPLC certificates.
Disclaimer: For laboratory research use only. Not approved for human use. Not medical advice.
Was this article helpful?
🔬 Related Research Peptides
Explore Research-Grade Peptides
HPLC-verified, lab-tested peptides for your scientific research. Fast delivery across the UAE.
Browse All PeptidesRelated Articles
Selected Research References
Selected scientific references for research context only. Products remain for laboratory research use and are not for human use.
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients
Emirates Peptides Research Team
A dedicated coalition of biochemists and clinical researchers focusing on advanced peptide synthesis and pharmacological applications. All data is verified against current clinical trials.
